Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720537 | 0.84 | HTR1A (0.36) | HTR1AADRA1DSMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL4724737 | 0.81 | HTR1A (0.38) | HTR1AADRA1DCHRM2CHRM4CHRM5 | |
| SCHEMBL4723802 | 0.79 | CYP2C9 (0.41) | HTR1AADRA1DSMN1; SMN2ALDH1A1 | |
| SCHEMBL4720972 | 0.76 | SLC6A3 (0.36) | ALOX5ALDH1A1 | |
| SCHEMBL4722980 | 0.74 | OPRM1 (0.35) | — | |
| SCHEMBL4721573 | 0.72 | SLC6A4 (0.37) | — | |
| SCHEMBL4724299 | 0.70 | BACE1 (0.31) | BACE1 | |
| SCHEMBL1255254 | 0.70 | HTR2A (0.41) | ALDH1A1 | |
| SCHEMBL10430315 | 0.68 | HTR2A (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL31367105 | 0.66 | HTR1A (0.43) | ALOX5HTR1AADRA1DCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | ALOX5 245/4885HTR1A 93/4885ADRA1D 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.